Trial Profile
A Double-Masked, Randomized, Placebo-Controlled Study of ALTY-0501 (Doxycycline 0.025% Ophthalmic Solution) for the Treatment of Dry Eye Administered QID for a 56 Day Period Utilizing the Controlled Adverse Environment Model
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 May 2014
Price :
$35
*
At a glance
- Drugs Doxycycline (Primary)
- Indications Dry eyes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Alacrity Biosciences
- 16 May 2014 New trial record